Trial
NCT02647762
CF101 Therapy Compared to Methotrexate Therapy for Active Rheumatoid Arthritis
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Can-Fite BioPharma
Collaborators
—
Condition
Rheumatoid Arthritis
Intervention
CF101 1 mg
Why stopped
Interim analysis results
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-12-19